Understanding Polyarteritis Nodosa (PAN)
At a Glance
Polyarteritis nodosa (PAN) is a rare autoimmune disease that causes severe inflammation and damage in medium-sized arteries. While historically linked to Hepatitis B, most cases today have no known cause. It is typically diagnosed using tissue biopsies, blood work, and specialized imaging tests.
Polyarteritis nodosa (PAN) is a very rare and serious form of vasculitis—a general term for inflammation of the blood vessels [1]. In PAN, your immune system mistakenly attacks your own arteries, specifically targeting the medium-sized ones that supply blood to your organs, skin, and nerves [2].
Being diagnosed with an “orphan disease” (a condition so rare it affects fewer than 200,000 people in the U.S.) can feel isolating, but understanding the biology of what is happening in your body is the first step toward taking control of your health journey [3].
How PAN Damages Your Arteries
The primary “injury” in PAN is necrotizing vasculitis, which means the inflammation severely damages the tissue within the vessel walls [4]. This damage typically happens in a “patchy” way along the length of an artery, leading to several structural changes. It is important to know that modern treatments are highly effective at halting this damage before it progresses [5].
- Arterial Narrowing: As the vessel wall swells and scars, the opening (lumen) gets smaller, which restricts blood flow to your organs and tissues [6].
- Microaneurysms: In some spots, the arterial wall becomes so weak that it bulges outward, forming tiny, balloon-like structures called microaneurysms [7]. On a medical imaging test called an angiogram, these often look like a “string of beads” [8].
- Rupture and Clotting: If left untreated, these weakened areas can occasionally burst, leading to internal bleeding, or they can trigger blood clots that completely block the artery, depriving tissue of oxygen (infarction) [6][9].
Why PAN is Different from Other Vasculitides
Doctors used to group many types of vasculitis together, but today, they use specific rules (like the Chapel Hill Consensus Conference guidelines) to tell them apart [10]. PAN is unique for two main reasons:
- Vessel Size: PAN targets medium-sized muscular arteries. It generally does not affect the very smallest vessels like capillaries or the tiny filters in the kidneys (glomeruli) [2][1]. This is why PAN patients usually do not have the specific type of kidney inflammation called glomerulonephritis [10].
- ANCA Status: Unlike other common forms of vasculitis (such as Microscopic Polyangiitis or MPA), PAN is typically ANCA-negative. ANCA (Anti-Neutrophil Cytoplasmic Antibodies) are proteins in the blood that often signal other types of vasculitis. If you test positive for ANCA, your doctor may look for a different diagnosis [10][11].
Triggers and Causes
In the past, many cases of PAN were triggered by the Hepatitis B virus (HBV) [12]. However, because of global vaccination programs, HBV-associated PAN has become extremely rare in many parts of the world [13].
Today, most people are diagnosed with idiopathic PAN, which means the exact cause is unknown [3]. In some cases, PAN-like symptoms are caused by rare genetic conditions like DADA2 (Deficiency of Adenosine Deaminase 2), which is important for your doctor to rule out, as the treatment may be different [14].
A Specialized Diagnosis
Because PAN can affect almost any part of the body—from your gut and heart to your skin and nerves—the symptoms can be confusing [5]. Doctors often use a combination of:
- Biopsy: Taking a small sample of affected tissue (like skin or nerve) to look for signs of necrotizing inflammation [15].
- Imaging: Using tests like angiography or PET/CT to look for microaneurysms or inflamed vessel walls [8][16].
- Blood Work: Checking for markers of inflammation and ensuring you are negative for ANCA or other mimicking conditions [11].
Common questions in this guide
What causes Polyarteritis Nodosa (PAN)?
How is PAN different from other types of vasculitis?
What are microaneurysms?
How do doctors diagnose Polyarteritis Nodosa?
Why might I need screening for the DADA2 genetic mutation?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my tests, am I classified as having 'idiopathic' PAN or have you identified a specific trigger like Hepatitis B?
- 2.Was my blood work negative for ANCA (Anti-Neutrophil Cytoplasmic Antibodies)? If it was positive, does that change my diagnosis to Microscopic Polyangiitis?
- 3.Do I have any microaneurysms, and which organs are currently affected?
- 4.Should I be screened for the DADA2 genetic mutation, especially if I have a family history or if my symptoms started early in life?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Single organ variant of polyarteritis nodosa in epididymis.
Garg K, Dawson L
Journal of cancer research and therapeutics 2015; (11(3)):662 doi:10.4103/0973-1482.138133.
PMID: 26458682 - 2
Comparing polyarteritis nodosa in children and adults: a single center study.
Erden A, Batu ED, Sönmez HE, et al.
International journal of rheumatic diseases 2017; (20(8)):1016-1022 doi:10.1111/1756-185X.13120.
PMID: 28626961 - 3
Idiopathic polyarteritis nodosa - does it still exist? Viewpoint 1: as our knowledge makes progress, idiopathic polyarteritis nodosa is fading away.
Watts RA
Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i79-i81 doi:10.1093/rheumatology/keae649.
PMID: 40071425 - 4
Temporal artery biopsy in polyarteritis nodosa: a case-based narrative literature review.
Fujikake T, Anegawa M, Wada S, et al.
Clinical rheumatology 2026; (45(7)):4675-4685 doi:10.1007/s10067-026-08183-y.
PMID: 42207464 - 5
Polyarteritis nodosa presenting with severe upper gastrointestinal bleeding: a case report.
Xiao XY, Niu Y, Liu PP, et al.
Journal of medical case reports 2024; (18(1)):616 doi:10.1186/s13256-024-04892-7.
PMID: 39707462 - 6
A Rare Presentation of Polyarteritis Nodosa.
Robinson C, Yasin Z, Patel P, Zebda H
Cureus 2022; (14(2)):e21925 doi:10.7759/cureus.21925.
PMID: 35273868 - 7
Wunderlich's syndrome as a manifestation of polyarteritis nodosa.
Beirão P, Teixeira L, Pereira P, Coelho ML
BMJ case reports 2017; (2017()) doi:10.1136/bcr-2016-218478.
PMID: 28137905 - 8
[Beware, polyarteritis nodosa still exists in nephrology!]
Perrin J, Carvelli J, Gondouin B, et al.
Nephrologie & therapeutique 2016; (12(6)):463-467 doi:10.1016/j.nephro.2016.03.007.
PMID: 27686032 - 9
Case report: Polyarteritis nodosa as a substrate for a massive myocardial infarction.
Solis-Jimenez F, Gonzalez-Ortiz A, Larios-Lara JH, et al.
Frontiers in cardiovascular medicine 2022; (9()):1070378 doi:10.3389/fcvm.2022.1070378.
PMID: 36712274 - 10
Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020.
Kawazoe M, Nanki T, Saeki K, et al.
Modern rheumatology 2024; (34(6)):1284-1287 doi:10.1093/mr/roae010.
PMID: 38343272 - 11
[Cutaneous alterations in vasculitides : Part 2: Special aspects of diseases of large, medium and small vessels].
Sunderkötter C, Michl C
Der Internist 2019; (60(8)):805-813 doi:10.1007/s00108-019-0642-3.
PMID: 31300830 - 12
[The changing face of medium-sized vasculitis].
Parada-Turska J, Turska M
Wiadomosci lekarskie (Warsaw, Poland : 1960) 2018; (71(1 pt 1)):64-72.
PMID: 29558354 - 13
Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005: Data from 196 patients.
Rohmer J, Nguyen Y, Trefond L, et al.
Journal of autoimmunity 2023; (139()):103093 doi:10.1016/j.jaut.2023.103093.
PMID: 37536165 - 14
Deficiency of adenosine deaminase 2 (DADA2): Review.
Sharma V, Deo P, Sharma A
Best practice & research. Clinical rheumatology 2023; (37(1)):101844 doi:10.1016/j.berh.2023.101844.
PMID: 37328410 - 15
Critical Limb Threatening Ischemia Due to Severe Polyarteritis Nodosa.
Yagi I, Yagi S, Nakanishi K, et al.
Internal medicine (Tokyo, Japan) 2025; (64(9)):1355-1358 doi:10.2169/internalmedicine.4149-24.
PMID: 39370254 - 16
Fluorodeoxyglucose positron emission tomography-computed tomography findings in a first series of 10 patients with polyarteritis nodosa.
Fagart A, Machet T, Collet G, et al.
Rheumatology (Oxford, England) 2022; (61(4)):1663-1668 doi:10.1093/rheumatology/keab591.
PMID: 34302460
This page provides educational information about Polyarteritis Nodosa (PAN) and its diagnosis. It is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from your healthcare provider.
Get notified when new evidence is published on Polyarteritis nodosa.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.